Repertoire Immune Medicines

Repertoire Immune Medicines is a biotechnology company dedicated to creating treatments for diseases based on the power of the human T cell repertoire to eliminate cancer cells, target pathogens and regulate immune function in autoimmune disease. Our proprietary DECODE platform is designed to provide a comprehensive understanding of the full repertoire of interactions between T cell receptors and their antigen targets that take place when diseased cells are present. This complex and intricate biological process is known as the immune synapse. We believe the ability to decipher these interactions represents one of the greatest opportunities for innovation in medical science. Repertoire's team operates from sites in Cambridge, Massachusetts and Zurich, Switzerland and uses its DECODE technology to rationally design treatments for cancers, autoimmune disorders and infectious diseases. To learn more about Repertoire Immune Medicines, please visit our website: www.repertoire.com.

Repertoire Immune Medicines Secures $189M Financing to Advance Pipeline Programs and Discovery Platform Directed at Cellular Immune Targets - JDRF T1D Fund

Suzanne Greco email address & phone number Repertoire Immune Medicines Vice President Finance contact information - RocketReach

Repertoire Immune Medicines Appoints B. Lynne Parshall to Board of Directors

Grace Yan, CMA - Repertoire Immune Medicines

Did irregular shifts in clinical trial progression at Flagship's Repertoire foreshadow the termination of its immuno-oncology program? - STAT

Repertoire Immune Medicines Secures $189M Financing to Advance Pipeline Programs and Discovery Platform Directed at Cellular Immune Targets

Andy Hurwitz, PhD • Repertoire Immune Medicines

Chutes & Ladders—Repertoire Immune Medicines, buzzing from $189M series B, taps Celgene vet as CMO

Repertoire Immune Medicines on X: Repertoire Immune Medicines to present new data from its DECODE™ platform program at FOCiS 2021. Read our press release here: #Focis #drugdevelopment #biotech / X

Thomas Malia - Director, Protein Sciences - Repertoire Immune Medicines